AUPH (Aurinia Pharmaceuticals Inc.) EV/Sales Multiple

auriniapharma.com (AUPH) - corporate logo

The enterprise value-to-revenue dynamics for Aurinia Pharmaceuticals (AUPH) confirm growing demand for lupus nephritis therapy driven by expanded insurance coverage. The indicator currently stands at 4870.45. Patents for the first systemic lupus erythematosus drug ensure stable sales. The company's resilience is based on its expansion into Asia and Europe via partner networks, which reduces dependence on the US market.

Aurinia Pharmaceuticals - AUPH EV/Sales Multiple (period 11/23/2025 - 11/20/2026)

Aurinia Corp - analytical breakdowns and key metrics (AUPH)

- current quotes and average value forecast:
- business market valuation indicators:
- cash and cash flow indicators:
Fundamental company valuation:AUPH - Aurinia Pharmaceuticals Inc.
Finished products of Aurinia Pharma

This ratio compares the total enterprise value to annual revenue, eliminating the impact of leverage on the valuation. By analyzing the EV/Sales trajectory, an investor determines the degree of asset overvaluation relative to its ability to generate cash flow. This metric allows one to filter out speculative noise from fundamental capitalization growth. For Aurinia Pharmaceuticals (AUPH), this indicator reflects market expectations regarding the commercialization of Lupkynis. Global distribution partnerships directly influence the dynamics of this multiple.

Direct competitors

ARGX - EV/Sales Multiple|BNTX: EV/Sales Multiple|ABVX (Abivax SA) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ADMA Corp|Enterprise Value-to-Revenue Multiple Protagonist Therapeutics PTGX|Company Value to Revenue IMVT (Immunovant Therapeutics)|Total Company Value-to-Revenue Ratio kiniksa.com|Enterprise Value-to-Revenue Ratio Grifols Biemat GRFS|Enterprise Value-to-Revenue Coefficient ADPT (Adaptive Biotechnologies Corporation)|celldex.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BioCryst Corp|VERA: EV/Sales Multiple|dianthustx.com (DNTH) - EV/Sales Multiple|PHVS (Pharvaris NV) - EV/Sales Multiple|ABCL: Business Value to Revenue|Enterprise Value-to-Revenue Ratio Tourmaline Bio, Inc. (TRML)|PGEN (Intrexon) - Business Value to Revenue|EV/Sales Multiple PHAR (Pharming Corp)|nektar.com (NKTR) - Enterprise Value-to-Revenue Multiple|UPB - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ZBIO (Zenas Biopharma)|IMNM: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Gossamer Bio, Inc. (GOSS)|Enterprise Value-to-Revenue Ratio KalVista Pharmaceuticals|Septerna Inc (SEPN) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PVLA|SVRA (Savara) - Business Value to Revenue|Rigel Pharma - Company Value to Revenue|Total Company Value-to-Revenue Ratio AnaptysBio Corp (ANAB)|ATXS: Company Value to Revenue|Business Value to Revenue ENGN (enGene Holdings Inc.)|RAPT Therapeutics Inc. (RAPT) - Enterprise Value-to-Revenue Ratio|Aerovate Therapeutics Inc (JBIO) - EV/Sales Multiple|ACRS (Aclaris Therapeutics, Inc) - EV/Sales Multiple|Kyverna (KYTX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple TLSA|Company Value to Revenue Cabaletta Bio, Inc. CABA|Ventyx Biosciences - Company Value to Revenue|THTX: Company Value to Revenue Ratio|AVTX - Enterprise Value-to-Revenue Ratio|ELDN: Enterprise Value-to-Revenue Ratio|Agenus Inc. (AGEN) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Climb Bio Inc|ZURA (Zura Bio Ltd) - EV/Sales Multiple|EV/Sales Multiple aTyr Pharma Inc|EV/Sales Multiple ADAG|Total Company Value-to-Revenue Ratio ImageneBio|EV/Sales Multiple STTK (Shattuck Labs Inc)|EV/Sales Multiple Equillium, Inc. EQ|CNTB - Enterprise Value-to-Revenue Ratio|Immunic Therapeutics (IMUX) - Company Value to Revenue|ATRA: EV/Sales Multiple|InflaRx GmbH (IFRX) - EV/Sales Multiple|XFOR (x4pharma.com) - EV/Sales Multiple|EV/Sales Multiple Adicet Bio|Enterprise Value-to-Revenue Ratio Celularity Inc (CELU)|Company Value to Revenue INmune Bio Corp INMB|Enterprise Value-to-Revenue Ratio Barinthus Biotherapeutics plc BRNS|KZR - Company Value to Revenue|sabbiotherapeutics.com - EV/Sales Multiple|akaritx.com (AKTX) - Company Value to Revenue|ENLV: EV/Sales Multiple|QTTB (Q32 Bio Inc) - Enterprise Value-to-Revenue Ratio|GOVX (geovax.com) - EV/Sales Multiple|EV/Sales Multiple Edesa Biotech Corp|EV/Sales Multiple IBIO|Company Value to Revenue Carisma Tx CARM|Enterprise Value-to-Revenue Ratio XTL Biopharmaceuticals Ltd XTLB|EV/Sales Multiple Bolt Biotherapeutics BOLT|HCW Biologics - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple aptevotherapeutics.com|AIM (AIM ImmunoTech, Inc.) - Company Value to Revenue|Aditxt Corp - Business Value to Revenue|GRI (GRI Bio Inc) - EV/Sales Multiple|EV/Sales Multiple XORTX Therapeutics Inc|Enterprise Value-to-Revenue Ratio Vyome Therapeutics (HIND)|REVB - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Indaptus Therapeutics, Inc. INDP|EV/Sales Multiple scinai.com SCNI|CalciMedica Inc - EV/Sales Multiple|AFMD - EV/Sales Multiple|ALLK: EV/Sales Multiple|Enterprise Value to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGMS (IGM Biosciences) - EV/Sales Multiple|ITOS: Business Value to Revenue|Company Value to Revenue OCEA (Ocean Biomedical)|TCBP: Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Third Harmonic Bio Inc THRD